Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

The drugmaker said it would launch late-stage trials of the drug after participants lost as much as 20% of their body weight.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

Eli Lilly and Novo Nordisk agree to expand access and cut prices for Zepbound and Wegovy • Medicare to begin covering obesity ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its ...

Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter, dragging the Swiss company's ...

Get the latest analysis on Heron Therapeutics (HRTX): current challenges, future outlook, and key growth factors. Click here ...